FDA warning letter: retatrutide and sermorelin products are unapproved new drugs
The December 2024 Xcel Research warning letter shows how FDA treats 'research use only' labels when website claims indicate intended human use.
On December 10, 2024, FDA warned Xcel Research LLC that its retatrutide, sermorelin, and other peptide products were unapproved new drugs and misbranded. The agency said 'research use only' labeling did not overcome the intended-use evidence from website claims.
Not legal or medical advice.
This page is for informational purposes only. Always verify the current official source or consult a qualified professional before making compliance, prescribing, purchasing, or clinical decisions. Read full disclaimer.
FDA's warning letter to Xcel Research LLC identified products labeled as RETA (retatrutide), sermorelin, and blends containing semaglutide and cagrilintide. The agency concluded that website claims about weight management, glucose control, and other therapeutic effects established intended use as drugs for human use.
Because no approved application was in effect for these products, FDA classified them as unapproved new drugs introduced in violation of sections 301(d) and 505(a) of the FD&C Act.
What did not change
The letter does not change the underlying status of the active ingredients. Retatrutide remains investigational; sermorelin remains without a currently marketed approved product; semaglutide remains approved only in its approved products.
Key takeaways
- ✓ Retatrutide is investigational; no FDA-approved product exists.
- ✓ Sermorelin's approved product (Geref) is discontinued from marketing.
- ✓ 'Research use only' labels do not shield products from FDA drug-status review.
What changed
FDA published a warning letter putting sellers on notice that retatrutide and sermorelin products marketed online are unapproved new drugs.
What did not change
No new approval or compounding pathway was created for these substances.
Next step
The firm must respond with corrective steps; FDA may take further action if violations continue.
Affected records
Controlling documents
- FDA Warning Letter to Xcel Research LLC
U.S. Food and Drug Administration, CDER Office of Compliance · Warning letter · 694608